Inhibition of fibrosis and improvement of function of the myopathic hamster cardiac muscle by halofuginone

Experimental and Clinical Cardiology

Volumn 20, Issue 1, 2014, Pages 2351-2383

  Fromes, Yves ^a   Bouyon, Sophie ^a   Nagi, Sadia ^a   Roussel, Veronique ^a   Genin, Olga ^b   Levi, Oshrat ^b   Pines, Mark ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b VOLCANI CENTER   (Israel)

Author keywords

Collagen; Cthrc1; Fibrosis; Halofuginone; Myofibroblasts

Indexed keywords

COLLAGEN; COLLAGEN ALPHA1 CHAIN; COLLAGEN TRIPLE HELIX REPEAT CONTAINING 1; COLLAGEN TYPE 1; HALOFUGINONE; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CELL NUCLEUS; COLLAGEN SYNTHESIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFICACY; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MYOFIBROBLAST; NONHUMAN; PROTEIN CROSS LINKING; SIGNAL TRANSDUCTION; SYRIAN HAMSTER; WEIGHT CHANGE;

EID: 84899768810     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Groh WJ. Arrhythmias in the muscular dystrophies. Heart Rhythm. 2012;9:1890-95.
2. Turillazzi E, Neri M, Riezzo I, Di Paolo M, Evangelisti L, Fineschi V. Cardiac fibrosis, arrhythmia and sudden death in myotonic dystrophy type 1: Could TGF-β1 improve the predictive accuracy of patients at risk, opening new therapeutic challenges? Int J Cardiol. 2013 [Epub ahead of print]
3. Kania G, Blyszczuk P, Eriksson U. Mechanisms of cardiac fibrosis in inflammatory heart disease. Trends Cardiovasc Med. 2009;19:247-52.
4. de Jong S, van Veen TA, van Rijen HV, de Bakker JM. Fibrosis and cardiac arrhythmias. J Cardiovasc Pharmacol. 2011;57:630-38.
5. Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2013 [Epub ahead of print].
6. Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology. 2006;118:10-24.
7. Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007;74:184-95. (Pubitemid 46517504)
8. Rosenkranz S, Flesch M, Amann K, et al. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol. 2002;283:H1253-62.
9. Schultz Jel J, Witt SA, Glascock BJ, et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest. 2002;109:787-96. (Pubitemid 34263155)
10. Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007;13:952-61. (Pubitemid 47222040)
11. Zeisberg EM, Kalluri R. Origins of cardiac fibroblasts. Circ Res. 2010;107:1304-12.
12. Hinz B, Phan SH, Thannickal VJ, et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012;180:1340-55.
13. Bujak M, Ren G, Kweon HJ, et al. Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation. 2007;116:2127-38. (Pubitemid 350060350)
14. Chapman D, Weber KT, Eghbali M. Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ Res. 1990;67:787-94. (Pubitemid 20315010)
15. Tanaka M, Fujiwara H, Onodera T, et al. Quantitative analysis of myocardial fibrosis in normal hearts, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J. 1986;55:575-81. (Pubitemid 16092908)
16. Spurney CF, Sali A, Guerron AD, et al. Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther. 2011;16(1):87-95.
17. Goehringer C, Rutschow D, Bauer R, et al. Prevention of cardiomyopathy in delta-sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors. Cardiovasc Res. 2009;82(3):404-10.
18. Elsherif L, Huang MS, Shai SY, et al. Combined deficiency of dystrophin and beta1 integrin in the cardiac myocyte causes myocardial dysfunction, fibrosis and calcification. Circ Res. 2008;102(9):1109-17 (Pubitemid 351667865)
19. Parsons SA, Millay DP, Sargent MA, et al. Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy. J Biol Chem. 2007;282(13):10068-78. (Pubitemid 47104644)
20. Pyagay P, Heroult M, Wang Q, et al. Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res. 2005;96:261-68. (Pubitemid 40209374)
21. LeClair R, Lindner V. The role of collagen triple helix repeat containing 1 in injured arteries, collagen expression, and transforming growth factor β signaling. Trends Cardiovasc Med. 2007;17:202-5. (Pubitemid 47089010)
22. Tano K, Mizuno R, Okada T, et al. MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett. 2010;584:4575-80.
23. Ip W, Wellman-Labadie O, Tang L, et al. Collagen triple helix repeat containing 1 promotes melanoma cell adhesion and survival. J Cutan Med Surg. 2011;15:103-10.
24. LeClair RJ, Durmus T, Wang Q, Pyagay P, Terzic A, Lindner V. cthrc1 is a novel inhibitor of transforming growth factor-beta signaling and neointimal lesion formation. Circ Res. 2007;100:826-33. (Pubitemid 46555687)
25. Li J, Cao J, Li M, et al. Collagen triple helix repeat containing-1 inhibits transforming growth factor-β1-induced collagen type I expression in keloid. Br J Dermatol. 2011;164:1030-6.
26. Tang L, Dai DL, Su M, Martinka M, Li G, Zhou Y. Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res. 2006;12:3716-22. (Pubitemid 44000252)
27. Spector I, Zilberstein Y, Lavy A, et al. The involvement of collagen triple helix repeat containing 1 in muscular dystrophies. Am J Pathol. 2013;182:905-16.
28. Cox GF, Kunkel LM. Dystrophies and heart disease. Curr Opin Cardiol. 1997;12:329-43. (Pubitemid 27252541)
29. Nigro V, de Sa Moreira E, Piluso G, et al. Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nat Genet. 1996;14:195-8. (Pubitemid 26338803)
30. Nigro V, Okazaki Y, Belsito A, et al. Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Genet. 1997;6:601-7. (Pubitemid 27142112)
31. Sakamoto A, Abe M, Masaki T. Delineation of genomic deletion in cardiomyopathic hamster. FEBS Lett. 1999;447:124-8. (Pubitemid 29134962)
32. Sakamoto A, Ono K, Abe M, Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, δ-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci USA. 1997;94:13873-8. (Pubitemid 28009677)
33. Ryoke T, Gu Y, Mao L, et al. Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition. Circulation. 1999;100:1734-43. (Pubitemid 29485257)
34. Pines M, Vlodavsky I, Nagler A. Halofuginone: From veterinary use to human therapy. Drug Dev Res. 2000;50:371-378.
35. Pines M. Targeting TGFβ signaling to inhibit fibroblasts activation as a therapy for fibrosis and cancer. Exp Opinion Drug Dis. 2008;3:11-20. (Pubitemid 351188342)
36. Levi-Schaffer F, Nagler A, Slavin S, Knopov V, Pines M. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: Effect of halofuginone. J Invest Dermatol. 1996;106:84-8. (Pubitemid 26053386)
37. Nagler A, Pines M. Topical treatment of cutaneous chronic graft versus host disease (cGvHD) with halofuginone: A novel inhibitor of collagen type I synthesis. Transplantation. 1999;68:1806-9. (Pubitemid 30004815)
38. Pines M, Domb A, Ohana M, et al. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone. Biochem Pharmacol. 2001;62:1221-7. (Pubitemid 33055626)
39. Nagler A, Firman N, Feferman R, Cotev S, Pines M, Shoshan S. Reduction in pulmonary fibrosis in vivo by halofuginone. Am J Resp Crit Care Med. 1996;154:1082-6.
40. Bruck R, Genina O, Aeed H, Alexiev R, Nagler A, Pines M. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001;33:379-86. (Pubitemid 32119026)
41. Turgeman T, Hagai Y, Huebner K, et al. Inhibition of Smad3 phosphorylation by halofuginone prevents muscle fibrosis and improves muscle performance in the mdx mouse model of Duchenne muscular dystrophy. Neuromuscul Disord. 2008;18:857-68.
42. Nevo Y, Halevy O, Genin O, et al. Fibrosis inhibition and muscle histopathology improvement in laminin-alpha2-deficient mice. Muscle Nerve. 2010;42:218-29.
43. Halevy O, Genin O, Barzilai-Tutsch H, et al. Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone. Histol Histopathol. 2013;28:211-26.
44. Huebner KD, Jassal DS, Halevy O, Pines M, Anderson JE. Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone. Am J Physiol Heart Circ Physiol. 2008;294:H1550-H61.
45. Mongue-Din H, Salmon A, Fiszman MY, Fromes Y. Periodic variation in R-R intervals and cardiovascular autonomic regulation in young adult Syrian hamsters. Am J Physiol Regul Integr Comp Physiol. 2009;296:R610-R7.
46. Rohr S. Myofibroblasts in diseased hearts: new players in cardiac arrhythmias? Heart Rhythm. 2009;6:848-56.
47. Weber KT, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol. 2013;10:15-26.
48. Schmierer B, Hill CS. TGFβ-SMAD signal transduction: molecular specificity and functional flexibility. Nat Cell Biol. 2007;8:971-82.
49. Stein M, Noorman M, van Veen TA, et al. Dominant arrhythmia vulnerability of the right ventricle in senescent mice. Heart Rhythm. 2008;5:438-48.
50. Suk T, Edwards C, Hart H, Christiansen JP. Myocardial scar detected by contrast enhanced cardiac magnetic resonance imaging is associated with ventricular tachycardia in hypertrophic cardiomyopathy patients. Heart Lung Circ. 2008;17:370-4.
51. Robinson TF, Geraci MA, Sonnenblick EH, Factor SM. Coiled perimysial fibers of papillary muscle in rat heart: morphology, distribution, and changes in configuration. Circ Res. 1988;63:577-92.
52. de Jong S, van Veen TA, de Bakker JM, van Rijen HV. Monitoring cardiac fibrosis: a technical challenge. Neth Heart J. 2012;20:44-8.
53. Segura AM, Frazier OH, Buja LM. Fibrosis and heart failure. Heart Fail Rev. 2012;[Epub ahead of print].
54. Turner NA, Porter KE. Function and fate of myofibroblasts after myocardial infarction. Fibrogen Tiss Rep. 2013;6:5.
55. Choi ET, Callow AD, Sehgal NL, Brown DM, Ryan US. Halofuginone, a specific collagen type I inhibitor, reduces anastomotic intimal hyperplasia. Arch Surg. 1995;130:257-61.
56. Popov Y, Patsenker E, Bauer M, Niedobitek E, Schulze-Krebs A, Schuppan D. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem. 2006;281:15090-8. (Pubitemid 43855098)
57. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-beta 1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol. 1997;29:1947-58. (Pubitemid 27303099)
58. Edgley AJ, Krum H, Kelly DJ. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β. Cardiovasc Ther. 2012;30:e30-e40.
59. Andreetta F, Bernasconi P, Baggi F, et al. Immunomodulation of TGF-beta 1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy. J Neuroimmunol. 2006;175:77-86.
60. Petrov VV, Fagard RH, Lijnen PJ. Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension. 2002;39:258-63. (Pubitemid 34165225)
61. van den Borne SW, Diez J, Blankesteijn WM, et al., Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol. 2010;7:30-7.
62. Carlson S, Trial J, Soeller C, Entman ML. Cardiac mesenchymal stem cells contribute to scar formation after myocardial infarction. Cardiovasc Res. 2011;91:99-107.
63. Zhou B, Pu WT. Epicardial epithelial-to-mesenchymal transition in injured heart. J Cell Mol Med. 2011;15:2781-3.
64. Kharaishvili G, Cizkova M, Bouchalova K, Mgebrishvili G, Kolar Z, Bouchal J. Collagen triple helix repeat containing 1 protein, periostin and versican in primary and metastatic breast cancer: an immunohistochemical study. J Clin Pathol. 2011;64:977-82.
65. Durmus T, LeClair RJ, Park KS, Terzic A, Yoon JK, Lindner V. Expression analysis of the novel gene collagen triple helix repeat containing-1 (Cthrc1). Gene Expr Patterns. 2006;6:935-40. (Pubitemid 44309445)
66. Rosker C, Salvarani N, Schmutz S, Grand T, Rohr, S. Abolishing myofibroblast arrhythmogenicity by pharmacological ablation of alpha-smooth muscle actin containing stress fibers. Circ Res. 2011;109:1120-31.
67. Yue L, Xie J, Nattel S. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Cardiovasc Res. 2011;89:744-53.